Dare Bioscience Inc (DARE)

02:22 AM

Daré Bioscience Engages Market with New Presentation - TipRanks

02:22 AM

Aug 28, 2025

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN

Aug 28, 2025

Aug 23, 2025

Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser

Aug 23, 2025

Aug 19, 2025

Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail

Aug 19, 2025

Aug 19, 2025

Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest

Aug 19, 2025

Aug 18, 2025

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 18, 2025

Aug 18, 2025

Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada

Aug 18, 2025

Aug 18, 2025

Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest

Aug 18, 2025

Aug 18, 2025

Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks

Aug 18, 2025

Aug 18, 2025

Dare Bioscience risks Nasdaq delisting over market value - MSN

Aug 18, 2025

Aug 15, 2025

Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest

Aug 15, 2025

Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest

Aug 15, 2025

Aug 15, 2025

Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest

Aug 15, 2025

Aug 15, 2025

Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN

Aug 15, 2025

Aug 15, 2025

Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Aug 15, 2025

Aug 15, 2025

Daré Bioscience Announces Q2 2025 Financial Results - TipRanks

Aug 15, 2025

Aug 14, 2025

Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest

Aug 14, 2025

Aug 14, 2025

Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest

Aug 14, 2025

Aug 14, 2025

Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest

Aug 14, 2025

Aug 14, 2025

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 14, 2025

Aug 14, 2025

Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada

Aug 14, 2025

Aug 14, 2025

Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener

Aug 14, 2025

Aug 14, 2025

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

Aug 14, 2025

Aug 14, 2025

Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan

Aug 14, 2025

Aug 08, 2025

Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView

Aug 08, 2025

Aug 07, 2025

Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest

Aug 07, 2025

Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire

Aug 07, 2025

Aug 07, 2025

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - The Manila Times

Aug 07, 2025

Aug 07, 2025

Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan

Aug 07, 2025

Jul 30, 2025

Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 30, 2025

Jul 29, 2025

Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest

Jul 29, 2025

Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire

Jul 29, 2025

Jul 29, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times

Jul 29, 2025

Jul 29, 2025

Revolutionary Female Viagra Cream DARE to PLAY Gets Major Launch Campaign Before Q4 Release - Stock Titan

Jul 29, 2025

Jul 25, 2025

Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks

Jul 25, 2025

Jul 23, 2025

Daré Bioscience Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - Autocar Professional

Jul 23, 2025

Jul 21, 2025

UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire

Jul 21, 2025

Jul 21, 2025

Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan

Jul 21, 2025

Jul 21, 2025

Daré Bioscience Unveils First Topical Sildenafil Cream for Women's Arousal, Set for Prescription Launch in Q4 2025 - Quiver Quantitative

Jul 21, 2025

Jul 17, 2025

Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider

Jul 17, 2025

Jul 16, 2025

Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties - TipRanks

Jul 16, 2025

Jul 15, 2025

Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada

Jul 15, 2025